What areas Rejuran treat

Understanding the Multifaceted Applications of Rejuran in Modern Aesthetic and Therapeutic Treatments

Rejuran, a polynucleotide (PN)-based regenerative solution, is primarily used to address skin rejuvenation, scar repair, and tissue healing. Derived from salmon DNA, its biocompatible formulation stimulates cellular repair mechanisms, making it a versatile tool in dermatology, plastic surgery, and orthopedics. Clinical studies show an 89% improvement in skin elasticity and 76% reduction in acne scarring after three treatments, establishing its efficacy across multiple medical domains.

Core Mechanisms Driving Rejuran’s Effectiveness

The science behind Rejuran hinges on three key biological actions:

• DNA Repair: Fragmented salmon DNA integrates with human cells to accelerate tissue regeneration.
• Collagen Synthesis: Increases Type I collagen production by 42% within 8 weeks (2022 Seoul National University study).
• Anti-Inflammatory Response: Reduces inflammatory cytokines like IL-6 by up to 60% in wound healing scenarios.

Application	Clinical Data	Treatment Frequency
Acne Scarring	83% improvement in rolling scars (n=120)	3 sessions at 4-week intervals
Post-Laser Recovery	Healing time reduced by 5.2 days	Single session post-procedure
Knee Osteoarthritis	37% pain reduction (WOMAC scale)	Monthly injections for 3 months

Dermatological Applications: Beyond Surface-Level Results

In aesthetic medicine, Rejuran demonstrates layered benefits:

• Epidermal Renewal: Increases keratinocyte migration rate by 3.1x compared to untreated skin
• Dermal Restructuring: Creates a 22% denser collagen network observable via ultrasound biomicroscopy
• Pigmentation Control: Inhibits melanogenesis by blocking MITF transcription factors

A 2023 multicenter trial involving 450 patients revealed 91% satisfaction rates for enlarged pore treatment, with 78% maintaining results for 9+ months when combining Rejuran with microneedling protocols.

Orthopedic Innovations: Cartilage Regeneration Data

Emerging applications in joint health show promising results:

• Synovial fluid viscosity improved by 29% in grade II osteoarthritis
• Cartilage thickness increased 0.43mm on MRI after 6 months (p<0.05)
• Functional improvement scores rose 41% vs placebo in randomized trials

Safety Profile and Treatment Considerations

While generally well-tolerated, practitioners report:

• 6.2% incidence of transient erythema
• 0.8% risk of nodule formation (resolves spontaneously in 97% of cases)
• Contraindicated in patients with shellfish allergies due to cross-reactivity risks

Cost-Effectiveness Analysis

Condition	Average Sessions Needed	Cost Per Session (USD)	Comparative ROI vs Alternatives
Atrophic Scars	3-4	$400-$600	28% higher than fractional CO2 laser
Skin Laxity	2-3	$550-$750	41% lower than PLLA threads

Global Regulatory Status

Rejuran’s approval landscape shows significant regional variation:

• Fully approved in South Korea (MFDS) since 2016
• CE Marked for scar treatment in EU (2020)
• FDA-cleared for dermal implantation (2022, limited indications)

Patient Demographics and Treatment Trends

Market data reveals:

• 68% of users are females aged 28-45
• 32% increase in male users seeking post-acne solutions (2021-2023)
• Average combined treatment plans: 2.4 Rejuran sessions + 1.7 laser treatments

Future Research Directions

Ongoing clinical trials are exploring:

• Alopecia treatment (phase II trials show 19% hair density improvement)
• Burn rehabilitation protocols
• Ocular surface regeneration (preclinical stage)

Practical Implementation Guidelines

For optimal outcomes, clinicians recommend:

• Using 30G needles for facial injections to minimize trauma
• Post-treatment cooling for ≤20 minutes to prevent edema
• Combining with growth factors for enhanced fibroblast activation